BioSpace News Archive

PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced a series of data presentations will illustrate outcomes with ropeginterferon alfa-2b among adults with polycythemia vera during the European Hematology Association’s Hybrid Congress, June 9-17 in Vienna, Austria.

Celularity Inc. announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market opens on June 27, 2022 according to a preliminary list of additions posted June 3, 2022.

Univar Solutions Inc., a leading global chemical and ingredient distributor and provider of value-added specialty services, will host “Innovation Day” on June 22.

Baxter International Inc., a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time.

Vertex Pharmaceuticals Incorporated announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT.

Orphazyme A/S, reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report.

Sciwind Biosciences Co., Ltd. announced that two abstracts have been accepted for poster presentations at The International Liver CongressTM 2022, the Annual Meeting of the European Association for the Studies of the Liver taking place June 22-26 in London, United Kingdom.

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs Conference.

Affini-T Therapeutics, Inc. , a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced three presentations at upcoming investor and industry conferences.

The Parker Institute for Cancer Immunotherapy and National Resilience, Inc. announced the launch of a five-year strategic alliance to develop next-generation cancer therapies generated from PICI’s network of leading immunotherapy research centers.